News | August 12, 2008

Skagit Valley Chooses Elekta Axesse to Treat Wider Range of Tumors

August 13, 2008 - The Elekta Axesse, which reportedly allows clinicians to treat cancer tumors more precisely and effectively throughout the entire body, has been added to the cancer treatment arsenal at Skagit Valley Hospital, Mount Vernon, WA.

"The addition of Elekta Axesse to our facility is great news for both clinicians and patients. Our clinicians will see a more efficient workflow while patients will get the benefit of shorter treatment times," said Peggy Perry, oncology service line director at Skagit Valley Hospital Regional Cancer Care Center. "It also means that we can treat up to 20 more patients a day for a wider range of tumors including those in the lung, liver and prostate."

The system’s advanced three-dimensional (3D) imaging capabilities are said to facilitate rapid, precise targeting of tumors, and the highly conformal radiation delivery system effectively treats tumors throughout the body while minimizing exposure to nearby healthy tissue. By planning in 3D and imaging patients in 3D prior to treatment, sub-millimeter accuracy can reportedly be achieved. The system's advanced software — including one integrated display monitor with treatment planning, electronic medical record (EMR) technology and system controls — helps clinician streamline workflow and cut treatment times for patients.

Skagit Valley Hospital Regional Cancer Care Center will take delivery of the Elekta Axesse in October.

For more information: www.elekta.com

Related Content

Proton Therapy Lowers Risk of Side Effects Compared to Conventional Radiation
News | Proton Therapy | May 23, 2019
Cancer patients getting proton therapy instead of traditional photon radiation are at a significantly lower risk of...
Henry Ford Hospital's ViewRay MRIdian linear accelerator system allows real-time MRI-guided radiotherapy. Shown is the support staff for this system. In the center of the photo is Benjamin Movsas, M.D., chair of radiation oncology at Henry Ford Cancer Institute. Second from the right is Carrie Glide-Hurst, Ph.D., director of translational research, radiation oncology.

Henry Ford Hospital's ViewRay MRIdian linear accelerator system allows real-time MRI-guided radiotherapy. Shown is the support staff for this system. In the center of the photo is Benjamin Movsas, M.D., chair of radiation oncology at Henry Ford Cancer Institute. Second from the right is Carri Glide-Hurst, Ph.D., director of translational research, radiation oncology.

Feature | Henry Ford Hospital | May 21, 2019 | Dave Fornell, Editor
Henry Ford Hospital thought leaders regularly speak at the radiation oncology and radiology conferences about new res
Varian Acquiring Cancer Treatment Services International
News | Radiation Therapy | May 21, 2019
Varian Medical Systems announced it has entered into a definitive agreement to acquire India’s Cancer Treatment...
Videos | Radiation Therapy | May 21, 2019
This is a walk through of the ViewRay MRIdian MRI-guided radiotherapy system installed at ...
Partial Breast Irradiation Effective, Convenient Treatment Option for Low-Risk Breast Cancer
News | Radiation Therapy | May 20, 2019
Partial breast irradiation produces similar long-term survival rates and risk for recurrence compared with whole breast...
New Method Improves Ability to Measure and Maximize Radiation Therapy Dose
News | Radiation Therapy | May 14, 2019
Delivering just the right dose of radiation for cancer patients is a delicate balance in their treatment regime....
Sponsored Content | Videos | Radiation Oncology | May 13, 2019
At ASTRO 2018, Accuray showcased new patient-fi
Radiotherapy After Chemo May Improve Survival in Advanced Hodgkin's Lymphoma Patients
News | Radiation Therapy | May 10, 2019
Patients with advanced Hodgkin's lymphoma who have large tumors at the time of diagnosis may benefit from radiotherapy...
IBA Partnering to Develop Advanced Digital Proton Therapy Technologies in Belgium
News | Proton Therapy | May 10, 2019
IBA (Ion Beam Applications SA) announced a research agreement with Skandionkliniken, Université Catholique de Louvain...